



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	I	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,534	10/089,534 03/28/2002		Ubaldo Armato	17642-59	5010
33717	7590	07/26/2005		EXAM	INER
		AURIG LLP	NAFF, DAVID M		
2450 COLORADO AVENUE, SUITE 400E SANTA MONICA, CA 90404			E	ART UNIT	PAPER NUMBER
	,	•		1651	

DATE MAILED: 07/26/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

· · · · · · · · · · · · · · · · · · ·	<u> </u>	Application No.	Applicant(s)			
		10/089,534	ARMATO ET AL			
Office Action Summary		Examiner	Art Unit			
		David M. Naff	1651			
Period fe	The MAILING DATE of this communica	tion appears on the cover sheet	with the correspondence address			
A SH THE - Exte after - If th - If NO - Faili Any	IORTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNICA ensions of time may be available under the provisions of 3 or SIX (6) MONTHS from the mailing date of this communical eperiod for reply specified above is less than thirty (30) do period for reply is specified above, the maximum statutoure to reply within the set or extended period for reply will, reply received by the Office later than three months after need patent term adjustment. See 37 CFR 1.704(b).	ATION.  7 CFR 1.136(a). In no event, however, may a cation.  ays, a reply within the statutory minimum of the complex of the c	a reply be timely filed  nirty (30) days will be considered timely.  DNTHS from the mailing date of this communication.  ABANDONED (35 U.S.C. § 133).			
Status			•			
1)2	Responsive to communication(s) filed of	on <u>10 May 2005</u> .				
2a)□		☐ This action is non-final.	•			
3)□						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
5)□ 6)⊠ 7)□	Claim(s) <u>13-26</u> is/are pending in the ap 4a) Of the above claim(s) <u>15 and 26</u> is/s Claim(s) <u>is/are allowed.</u> Claim(s) <u>13,14 and 16-25</u> is/are rejected Claim(s) <u>is/are objected to.</u> Claim(s) <u>are subject to restriction</u>	are withdrawn from consideratio	n.			
Applicat	ion Papers					
10)	The specification is objected to by the E The drawing(s) filed on is/are: a Applicant may not request that any objectio Replacement drawing sheet(s) including the	)☐ accepted or b)☐ objected to on to the drawing(s) be held in abey e correction is required if the drawir	ance. See 37 CFR 1.85(a). ng(s) is objected to. See 37 CFR 1.121(d).			
11)[	The oath or declaration is objected to by	y the Examiner. Note the attach	ed Office Action or form PTO-152.			
Priority	under 35 U.S.C. § 119					
а)	Acknowledgment is made of a claim for All b) Some * c) None of:  1. Certified copies of the priority do: 2. Certified copies of the priority do: 3. Copies of the certified copies of the application from the International See the attached detailed Office action for the certified copies of the attached detailed Office action for the attached detailed Office action f	cuments have been received. cuments have been received in the priority documents have bee I Bureau (PCT Rule 17.2(a)).	Application No In received in this National Stage			
Attachmer	nt(s)					
2)  Notio	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO- mation Disclosure Statement(s) (PTO-1449 or PTo- er No(s)/Mail Date	-948) Paper No	v Summary (PTO-413) b(s)/Mail Date f Informal Patent Application (PTO-152) 			

Application/Control Number: 10/089,534 Page 2

Art Unit: 1651

5

15

#### DETAILED ACTION

A response of 5/10/05 to a restriction requirement of 4/20/05 elected with traverse invention I claims 13, 14 and 16-25.

The traverse is on the ground that a search for invention I will necessarily encompass a search for invention II. However, due to differences in conditions required by the different methods of inventions I and II, invention I can be searched without searching for invention II, or the converse. The traverse is unpersuasive, and the restriction requirement is adhered to and made final.

Claims 15 and 26 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 5/10/05.

Claims examined on the merits are 13, 14 and 16-25.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

### Claim Rejections - 35 USC § 112

Claims 16-21, 23 and 24 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Art Unit: 1651

10

15

20

Support for these claims in the specification is not readily apparent. Applicants have pointed to pages for support. However, support is not found on the pages cited. Pages 16 and 17 are indicated as supporting claims 16-18. However, these pages list publications as bibliographic sources. Page 18, lines 21-23, does not disclose claim 19, and page 19, lines 14-26, does not disclose claim Claim 21 is not found at page 21, lines 7-9. Page 15 like pages 16 and 17 lists bibliographic sources, and does not disclose claims 23 and 24.

## Claim Rejections - 35 USC § 112

Claims 13, 14 and 16-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Bridging lines 1 and 2 of claim 13, "bio-membrane using---fibroin" is unclear as to how the membrane uses the fibroin. appears "using" should be replaced with --- including ---.

The term bio-membrane in line 1 of claim 13 is uncertain as to meaning and scope. How does "bio" define the membrane? Additionally, structure that is a membrane and not a membrane is unclear since no structure that defines a membrane is required.

In line 4 of claim 13, the meaning and scope of "specialized tissue cells" is uncertain. Whether a cell is "specialized" is relative and subjective.

Art Unit: 1651

10

15

20

In line 3 of claim 21, the meaning and scope of "normal cytological features" is uncertain. Being "normal" is relative and subjective.

Bridging lines 1 and 2 of claim 23, "includes comprises" is uncertain as to meaning.

## Claim Rejections - 35 USC § 103

Claims 13, 14 and 16-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Santin et al or Gotoh et al (listed on form 1449) in view of Minoura et al and Naughton et al (4,963,489) (both newly applied), and if necessary in further view of Bell (6,398,819) (newly applied).

The claims are drawn to forming tissue by seeding cells on a biomembrane including crystalline beta-form fibroin, and proliferating and differentiating the cells to form tissue.

Santin et al and Gotoh et al disclose preparing a fibroin film in the same way as described in the present specification when preparing a fibroin membrane. The film adheres cells, and the fibroin film is formed on synthetic polymer plate or film. See Santin et al (page 383 under "Sample preparation"), and Gotoh et al (page 352, under "Preparation of aqueous solutions of NSF and RSF" and "Preparation of SF matrices for cell culture experiments").

Minoura et al disclose attachment and growth of fibroblast cells on silk protein matrices. The proteins exhibited as high a cell attachment and growth as collagen widely used as a cell culture

Application/Control Number: 10/089,534 Page 5

Art Unit: 1651

5

10

15

20

25

substrate (sentence bridging the columns in the abstract on page 1215).

Naughton et al disclose growing cells to produce tissue on a collagen substrate (col 1, line 36, and col 38, lines 37-38).

Bell discloses producing tissue by culturing cells on an extracellular matrix scaffold formed of collagen. For example, see col 1, line 56 to col 2, line 14, and col 6, line 8.

It would have been obvious to use the fibroin film of Santin et al or Gotoh et al as a substrate for culturing cells to produce tissue as suggested by Minoura et al disclosing that silk protein matrices exhibit as high a cell attachment and growth as collagen and Naughton et al disclosing growing cells to produce tissue on a collagen substrate, and if needed, by Bell disclosing using an extracellular matrix formed of collagen for culturing cells to produce tissue. fibron of Santin et al or Gotoh et al is crystalline beta-form. Growing cells to produce tissue will inherently result in proliferation and differentiation. The conditions of dependent claims would have been matters of obvious choice in view of the disclosures of the references. Using specific cells or cells from a specific source would have been obvious to obtain tissue produced by the specific cells or cells from the source. Providing glucose to the cells as in claim 18 would have been obvious when the cells utilize glucose as a nutrient source. Pre-irradiated cells as in claim 21 encompasses exposing cells to light. Cells grown on the film of Santin et al or Gotoh et al will inherently be exposed to light before Application/Control Number: 10/089,534 Page 6

Art Unit: 1651

5

10

15

culturing. The film of Santin et al or Gotoh et al will contain an amount of fibroin as required by claim 25.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David M. Naff whose telephone number is 571-272-0920. The examiner can normally be reached on Monday-Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 751-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David M. Naff Primary Examiner Art Unit 1651

DMN

20